A Phase 1 Placebo-Controlled Study To Assess Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 Administered In A Tablet Formulation In Otherwise Healthy Overweight And Obese Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2013
At a glance
- Drugs PF 5175157 (Primary) ; Midazolam
- Indications Anxiety disorders; Sleep disorders; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- 16 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Aug 2013 Planned End Date changed from 1 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 01 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.